Bulk Manufacturer of Controlled Substances Application: S & B PHARMA, INC., 38564 [2014-15888]

Download as PDF 38564 Federal Register / Vol. 79, No. 130 / Tuesday, July 8, 2014 / Notices also be submitted electronically to jtrelease@osmre.gov. To request a copy of the information collection request contact John Trelease at (202) 208–2783 or via email at jtrelease@osmre.gov. SUPPLEMENTARY INFORMATION: OMB regulations at 5 CFR 1320, which implement provisions of the Paperwork Reduction Act of 1995 (Pub. L. 104–13), require that interested members of the public and affected agencies have an opportunity to comment on information collection and recordkeeping activities [see 5 CFR 1320.8(d)]. This notice identifies an information collection that OSMRE will be submitting to OMB for extension. This collection is contained in 30 CFR Part 870—Abandoned Mine Reclamation Fund—Fee Collection and Coal Production Reporting, and the implementing form OSM–1—Coal Reclamation Fee Report. OSMRE will request a 3-year term of approval for this information collection activity. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. The OMB control number for this collection is 1029–0063. Responses are mandatory. Comments are invited on: (1) The need for the collection of information for the performance of the functions of the agency; (2) the accuracy of the agency’s burden estimates; (3) ways to enhance the quality, utility and clarity of the information collection; and (4) ways to minimize the information collection burden on respondents, such as use of automated means of collection of the information. A summary of the public comments will be included in OSMRE’s submission of the information collection request to OMB. Before including your address, phone number, email address, or other personal identifying information in your comment, you should be aware that your entire comment—including your personal identifying information—may be made publicly available at any time. While you can ask us in your comment to withhold your personal identifying information from public review, we cannot guarantee that we will be able to do so. Title: 30 CFR Part 870—Abandoned Mine Reclamation Fund—Fee Collection and Coal Production Reporting. OMB Control Number: 1029–0063. Summary: The information is used to maintain a record of coal produced for sale, transfer, or use nationwide each calendar quarter, the method of coal tkelley on DSK3SPTVN1PROD with NOTICES FOR FURTHER INFORMATION CONTACT: VerDate Mar<15>2010 16:48 Jul 07, 2014 Jkt 232001 removal and the type of coal, and the basis for coal tonnage reporting in compliance with 30 CFR Part 870 and section 401 of Public Law 95–87. Individual reclamation fee payment liability is based on this information. Without the collection of information OSMRE could not implement its regulatory responsibilities and collect the fee. Bureau Form Number: OSM–1. Frequency of Collection: Quarterly. Description of Respondents: Coal mine permittees. Total Annual Responses: 8,792. Total Annual Burden Hours: 810. Dated: July 2, 2014. John A. Trelease, Acting Chief, Division of Regulatory Support. In accordance with 21 CFR 1301.33(a), this is notice that on December 10, 2013, S & B Pharma, Inc., DBA Norac Pharma, 405 South Motor Avenue, Azusa, California 91702–3232, applied to be registered as a bulk manufacturer of the following basic classes of narcotic or nonnarcotic controlled substances: Controlled substance Gamma Hydroxybutyric (2010) .... Tetrahydrocannabinols (7370) ..... Methamphetamine (1105) ............ Pentobarbital (2270) ..................... Nabilone (7379) ............................ 4-Anilino-N-phenethyl-4-piperidine (8333). Tapentadol (9780) ........................ Fentanyl (9801) ............................ Schedule I I II II II II II II [FR Doc. 2014–15928 Filed 7–7–14; 8:45 am] The company plans to manufacture the listed controlled substances in bulk for use in product development and for commercial sales to its customers. BILLING CODE 4310–05–P DEPARTMENT OF JUSTICE Drug Enforcement Administration [Docket No. DEA–392] Bulk Manufacturer of Controlled Substances Application: S & B PHARMA, INC. ACTION: Registered bulk manufacturers of the affected basic classes and applicants therefore, may file written comments on or objections to the issuance of the proposed registration in accordance with 21 CFR 1301.33(a) on or before September 8, 2014. ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/ODW, 8701 Morrissette Drive, Springfield, Virginia 22152. DATES: The Attorney General has delegated his authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, and dispensers of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Deputy Assistant Administrator of the DEA Office of Diversion Control (‘‘Deputy Assistant Administrator’’) pursuant to sec. 7(g) of 28 CFR pt. 0, subpt. R, App. PO 00000 Frm 00083 Fmt 4703 Sfmt 4703 [FR Doc. 2014–15888 Filed 7–7–14; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF LABOR Notice of application. SUPPLEMENTARY INFORMATION: Dated: July 1, 2014. Joseph T. Rannazzisi, Deputy Assistant Administrator. Office of the Secretary Agency Information Collection Activities; Submission for OMB Review; Comment Request; Powered Platforms for Building Maintenance Standard ACTION: Notice. The Department of Labor (DOL) is submitting the Occupational Safety and Health Administration (OSHA) sponsored information collection request (ICR) titled, ‘‘Powered Platforms for Building Maintenance Standard,’’ to the Office of Management and Budget (OMB) for review and approval for continued use, without change, in accordance with the Paperwork Reduction Act of 1995 (PRA), 44 U.S.C. 3501 et seq. Public comments on the ICR are invited. DATES: The OMB will consider all written comments that agency receives on or before August 7, 2014. ADDRESSES: A copy of this ICR with applicable supporting documentation; including a description of the likely respondents, proposed frequency of response, and estimated total burden may be obtained free of charge from the RegInfo.gov Web site at http:// www.reginfo.gov/public/do/ SUMMARY: E:\FR\FM\08JYN1.SGM 08JYN1

Agencies

[Federal Register Volume 79, Number 130 (Tuesday, July 8, 2014)]
[Notices]
[Page 38564]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-15888]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-392]


Bulk Manufacturer of Controlled Substances Application: S & B 
PHARMA, INC.

ACTION: Notice of application.

-----------------------------------------------------------------------

DATES: Registered bulk manufacturers of the affected basic classes and 
applicants therefore, may file written comments on or objections to the 
issuance of the proposed registration in accordance with 21 CFR 
1301.33(a) on or before September 8, 2014.

ADDRESSES: Written comments should be sent to: Drug Enforcement 
Administration, Attention: DEA Federal Register Representative/ODW, 
8701 Morrissette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: The Attorney General has delegated his 
authority under the Controlled Substances Act to the Administrator of 
the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority 
to exercise all necessary functions with respect to the promulgation 
and implementation of 21 CFR part 1301, incident to the registration of 
manufacturers, distributors, and dispensers of controlled substances 
(other than final orders in connection with suspension, denial, or 
revocation of registration) has been redelegated to the Deputy 
Assistant Administrator of the DEA Office of Diversion Control 
(``Deputy Assistant Administrator'') pursuant to sec. 7(g) of 28 CFR 
pt. 0, subpt. R, App.
    In accordance with 21 CFR 1301.33(a), this is notice that on 
December 10, 2013, S & B Pharma, Inc., DBA Norac Pharma, 405 South 
Motor Avenue, Azusa, California 91702-3232, applied to be registered as 
a bulk manufacturer of the following basic classes of narcotic or 
nonnarcotic controlled substances:

------------------------------------------------------------------------
            Controlled substance                       Schedule
------------------------------------------------------------------------
Gamma Hydroxybutyric (2010)................  I
Tetrahydrocannabinols (7370)...............  I
Methamphetamine (1105).....................  II
Pentobarbital (2270).......................  II
Nabilone (7379)............................  II
4-Anilino-N-phenethyl-4-piperidine (8333)..  II
Tapentadol (9780)..........................  II
Fentanyl (9801)............................  II
------------------------------------------------------------------------

    The company plans to manufacture the listed controlled substances 
in bulk for use in product development and for commercial sales to its 
customers.

    Dated: July 1, 2014.
Joseph T. Rannazzisi,
Deputy Assistant Administrator.
[FR Doc. 2014-15888 Filed 7-7-14; 8:45 am]
BILLING CODE 4410-09-P